

บรรณานุกรม

- กัลยา วนิชย์บัญชา. 2545. การใช้ SPSS for Window ในการวิเคราะห์ข้อมูล. กรุงเทพฯ : ซี เค แอนด์ เอส ไฟฟ์สตูดิโอ.
- ขวัญชัย พุกรัตน์กิจญ์โภ. 2544. “Natural History of HIV infection”, ใน: Current Practice in Common Infectious Disease หน้า 467-486. สมบัติ ลีลาสุภาครี, สถาพร นิติวิเชียรเลิศ, ชนพันธ์ พิมูลย์บรรณกิจ และ กิตติ ตระกูลอุน, บรรณธิการ. กรุงเทพฯ : สาขาวิชาญกร พิมพ์.
- สงขลานครินทร์, มหาวิทยาลัย. ศูนย์คอมพิวเตอร์. 2546. เอกสารประกอบการอบรม SPSS for window. สงขลา.
- สภาพแวดล้อม. 2544. “ปัญหาที่เกี่ยวกับการใช้ยา”ยกตัวอย่างเชิงประยุกต์ ของสภาพแวดล้อม พ.ศ. 2544. (สำเนา)
- สำนักโรคเอดส์ วัน โรคและโรคติดต่อทางเพศสัมพันธ์. 2547. “แนวทางปฏิบัติงานโครงการการเข้าถึงบริการยาต้านไวรัสเอดส์ระดับชาติสำหรับผู้ติดเชื้อและผู้ป่วยเอดส์”
- อรรถพ หิรัญดิษฐ์. 2544. “การบริบาลทางเภสัชกรรมในคลินิก HIV ณ โรงพยาบาลพระมงกุฎเกล้า”, วิทยานิพนธ์เภสัชศาสตรมหาบัณฑิต สาขาวิชาเภสัชกรรมคลินิก มหาวิทยาลัยมหิดล. (สำเนา)
- Bamble, C.M., Evans, B.L. and Shevchuk, Y.M. 1999. “A pilot project implementing pharmaceutical care and continuity of care in a ambulatory HIV clinic”, Can J Hosp Pharm. 52, 156-161.
- Bangsberg, D.R., Hecht, F.M., Charlbois, E.D. 2000. “Adherence protease inhibitors, HIV-1 viral load and development of drug resistance in an indigent population”, AIDS. 14, 357- 366.
- Barreiro, P., Soriano, V., Casas, E., Estrada, V., Tellez, M.J. and Hoetelmans, R.2000. “Prevention of nevirapine associated exanthema using slow dose escalation and or corticosteroids”, AIDS. 14, 2153-2157.
- Berg, J.S., Dischler, J., Wagner, D.L., Raia J.J. and Palmer-shevlin, N. 1993 “Medication compliance: a health care problem”, Ann Pharmacother. 27, s3-s19.
- Brinkman, K., Smeitink, J.A., Romijn, J.A and Reiss P. 1999. “Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in pathogenesis

- of antiretroviral therapy related lipodystrophy”, Lancet. 354, 1112-1115.
- Cameron, D.W., Health-Chiozzi, M. and Danner, S. 1998. “Randomized placebo controlled trial of ritonavir in advanced HIV-1”, Lancet. 351(9102), 543-9.
- Cantwell-McNelis, K. and James C.W. 2002. “Role of clinical pharmacists in outpatient HIV clinics”, Am J Health-Syst Pharm. 59, 447-452.
- Centres for Disease Control and Prevention. 1993 revise. Classification for HIV infection and expanded surveillance case definition for AIDS among adolescents and adult. MMWR. 1992; 41(RR-17), 1-19.
- Chesney, M.A. 2000. “Factors affecting adherence to antiretroviral therapy”, Clin Infect Dis. 30(suppl2), s171-6.
- Chinen, J. and Shearer W.T. 2002. “Molecular virology and immunology of HIV infection”, J Allergy Clin Immunol. 110, 189-98.
- Colombo, J. 1997. “Establishing pharmaceutical care services in an HIV clinic”, J Am Pharm(wash). NS37, 581-92.
- Cramer, J.A. 1991. “Overview of method to measure and enhance patient compliance”, In: patient compliance in medical practice and clinic trials, pp. 3-10. Cramer, J.A., Spilker B., eds. New York: Raven press.
- Deng, H.K., Lui, R. and Ellmeier, W. 1996. “Identification of a major co-receptor primary isolates of HIV-1”, Nature. 381, 661-666.
- Department of Health and Human Services. 2003. Guideline for the use of antiretroviral agents In HIV-1-infected adults and adolescents. Available at <http://AIDSInfo.nih.gov>. Accessed 14 July 2003.
- Dragic, T., Litwin, V. and Allaway, G.P. 1996. “HIV-1 entry into CD4 cell is mediated by the chemokines receptor CC-CXR-5”, Nature. 381, 667-73.
- Fauci, A.S., Pantaleo, G., Stanley, S., Weissman, D. 1996. “Immunopathogenic mechanisms of HIV infection”, Ann Intern Med. 124, 654-663.
- Feng, Y., Broder, C.C., Kennedy, P.E., Berger, E.A. 1996. “HIV-1 entry cofactor: functional cDNA cloning of seven-transmembrane G protein coupled receptor”, Science. 276, 872-877.
- Finzi, D., Hermankova, M. and Pierson, T. 1997. “Identification of a reservoir for HIV-1 in

- patients on highly active antiretroviral therapy”, Science. 278, 1295-1300.
- Foisy, M.M., Tseng, A. and Blakie, N. 1996. “Pharmacists’ provision of continuity of care to patients with human immunodeficiency virus infection”, Am J Health-Syst Pharm. 53, 1013-1017.
- Foisy, M.M. and Akai, P.S. 2004. “Pharmaceutical care for HIV patients on directly observed therapy”, Ann Pharmacother. 38, 550-556.
- Fowler, M.E. 1998 “Recognizing the phenomenon of readiness: concept analysis and case study”, J Assoc Nurse AIDS Care. 9(3), 72-76.
- Friedland, G.H., Andrews, L.A. 2001. “Adherence to antiretroviral therapy”, AIDS Rev. 3, 111-120.
- Gao, F., Bailes, E. and Robertson, D.L. 1999. “Origin of HIV-1 in the chimpanzee pantroglodyte”, Nature. 397, 436-441.
- Geletko, S.M., Poulakos, M.N. 2002. “Pharmaceutical services in an HIV clinic”, Am J Health-Syst Pharm. 59, 709-713.
- Gifford, A.L., Bormann, J.E., Shively, M.J., Wright, B.C., Richman., D.D. and Bozzette, S.A. 2000. “Predictors of self-reported adherence and plasma HIV concentrations in patients on multi drug antiretroviral regimens”, J Acquir Immune Defic Syndr. 23, 386-395.
- Graham, K.K., Beeler, L.H. and Plasencia,C.L. “Development and justification of a pharmacist base HIV medication adherence referral clinic”. ACCP/ESCP proceeding, Orlando, 1999. Poster n 277. (abstract)
- Greco, R., Lavack, L. and Rovers, J. 1992. “Assessment of the pharmacy service needs of HIV positive outpatients receiving zidovudine”, Ann Pharmacother. 26, 621-626.
- Goujard, C., Bernard, N., Shier, N., Peyramond, D., Lancon, F. and Chwallow, M.J. 2003. “Impact of a patient education program on adherence to HIV medication”, J Acquir Immune Defic Syndr. 34, 191-194.
- Gulick, R.M., Mellors, J.W. and Havlir, D. 1997. “Treatment with indinavir zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy”, N Engl J Med. 337 (11), 734-739.
- Hahn, B., Shaw, G.M., De Cook, K.M., Sharp, P.M. 2000. “AID as a zoonosis: scientific and

- public health implications”, Science. 287, 607-614.
- Hammer, S.M., Squires, K.E. and Hughes, M.D. 1997. “A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 2000 per cubic millimeter or less”, N Engl J Med. 337(11), 725-733.
- Hatoum, H.T., Hutchinson, R.A., Witte, K.W. and Newby, G.P. 1988. “Evaluation of the contribution of clinical pharmacists:inpatient care and cost reduction”, Drug Intell Clin Pharm. 22, 252-259.
- Haubrich, R.H., Little, S.J., Currier, J.S., Forthal, D.N., Kemper, C.A., Beall, G.N. 1999. “The value of patient-reported adherence to adherence to antiretroviral therapy in predicting virologic and immunologic response”, AIDS. 13, 1099-1107.
- Helper, C.D. and Strand, L.M. 1990. “Opportunistic and responsibilities in pharmaceutical care”, Am J Hosp Pharm. 47, 533-543.
- Ho, C.F., Fong, O.W. and Wong, K.H. 2002. “Patient self reports as a marker of adherence to antiretroviral therapy”, Clin Infect Dis. 34, 1534-1535.
- King, J.L., Schommer, J.C. and Wirsching, R.G. 1998. “Patients’knowledge of medication care plans after hospital discharge”, Am J Health-Syst Pharm. 55, 1389-1393.
- Knobel, H., Carmona, A., Lopez, J.C., Saballs, P., Gonzalez, A. and Diez, A. 1999. “Adherence to highly active antiretroviral treatment : impact of individualized assessment”, Eferm Infect Microbio Clin. 17, 78-81.
- Knobel, H., Alonso, J., Casado, J.L., Collazos, J., Gonzalez, J. and Ruiz I. 2002. “Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study”, AIDS. 16, 605-613.
- Laurent, C., Kouanfack, C., Koulla-Shiro, S., Nkoue, N., Bourgwois, A. and Calmy, A. 2004. “Effectiveness and safety of a generic fixed-dose combination of nevirapine stavudine and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial”, Lancet. 364, 29-34.
- Lederman, M., Connick, E. and Landay, A. 1998. “Partial immune reconstitution after 12 weeks of HAART (AZT,3TC,ritonavir). Preliminary result of ACTG315”, J Infect Dis. 178, 70-79.

- Little, S.J., Mclean, A.R., Spina, C.A., Richman, D.D., Havlir, D.V. 1999. "Viral dynamics of acute HIV-1 infection", J Exp Med. 190, 841-850.
- Lucas, G.M., Chaisson, R.E., Moore, R.D. 1999. "Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions", Ann Intern Med. 131(2), 81-87.
- Maat, M.M., Boer, A., Kok, C.H., Mulder, J.W., Meenhoret. P.L, Gorp E.C.M., Mairuhut, A. T., Huitema, A.D. and Beijnen, J.H. 2004. "Evaluation of clinic pharmacist interventions on drug interations in outpatient pharmaceutical HIV-care", J Clin Pharm Ther. 29, 121-130.
- Mannheimer, S., Friedland, G., Matts, J., Child, C. and Chesney, M. 2002. "The consistency of adherence to antiretroviral therapy predict biologic outcomes for human immunodeficiency virus infected persons in clinical trial", Clin Infect Dis. 34, 1115-1121.
- Max, B. and Sherer, R. 2000. "Management of the adverse effects of antiretroviral therapy and medication adherence", Clin Infect Dis. 30(suppl2), s96-s116.
- Melbourne, K.M., Brown, S.L., Dufresne, R.L., Geletko, S.M. 1999. "Impact of pharmaceutical care on outcomein HIV infected individuals", The AIDS Reader. 9, 329-338.
- Mellors, J.W., Munoz, A. and Giorgi, J. 1997. "Plasma viral load and CD4 lymphocyte as prognostic markers of HIV-1 infection", Ann Intern Med. 126, 946-954.
- Miedema, F., Klein, M.R. 1996. "AID pathogenesis: a finite immune response to blame", Science. 272, 505-506.
- Montaner, J.SG., Reiss, P.and Cooper, D. 1998. "A randomized double blind trial comparing combinations of nevirapine didanosine and zidovudine for HIV infected patients.The INCAS trial", JAMA. 279, 930-937.
- Moonis, M., Lee, B., Bailer, R.T., Luo, Q. and Montaner, L.J. 2001. "CCR5 and CXCR4 expression correlated with x4 and x5 HIV-1 infection yet not sustained replication in Th1 and Th2 cells", AIDS. 15, 1941-1949.
- Morisky, D.E., Green, L.W. and Levine, D.M. 1986. "Concurrent and predictive validity of a Self reported measure of medication adherence", Med Care. 24, 67-74.
- Morrison, A. and Wertheimer, A.I. 2001. "Evaluation of studies investigating the effectiveness

- Of pharmacists'clinical service", Am J Health-Syst Pharm. 58, 569-577.
- Naranjo, C.A. 1981. "A method for estimating the probability of adverse drug reaction", Clin Pharmacol Ther. (August), 239-245.
- Nicols-English, D. and Poirier, S. 2000. "Optimizing adherence to pharmaceutical care plans", J Am Pharm Assn. 40, 475-485.
- Oh, Y., McCombs, J.S., Cheng, R.A. and Johnson, K.A. 2002. "Pharmacist time requirements for counseling in an outpatient pharmacy", Am J Health-Syst Pharm. 59, 2346-2355.
- Ostrop, N.J., Hallett, K.A., Gill, M.J. 2000. "Long term patient adherence to antiretroviral therapy", Ann Pharmacother. 34, 703-709.
- Overhage, J.M. and Lukes, A. 1999. "Practical reliable comprehensive method for characterizing pharmacists'clinical activities", Am J Health-Syst Pharm. 56, 2444-2450.
- Pantaleo G., Graziosi, C. and Demarest, J.F. 1993. "HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease", Nature. 362, 355-358.
- Paterson, D.L., Swindells, S., Mohr J., Brester, M., Vergis, E.N., Squier, C. and Wagener, M.M. 2000. "Adherence to protease inhibitor therapy and outcomes in patients with HIV infection", Ann Intern Med. 133, 21-30.
- Paterson, D.L., Potoski, B. and Capitano, B. 2002. "Measurement of adherence to antiretroviral medication", J Acquir Immune Defic Syndr. 31, s103-s106.
- Perelson, A.S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A. and Saksela, K. 1997. "Decay characteristic of HIV-1 infected compartments during combination therapy", Nature. 387, 188-191.
- Report on the global HIV/AIDS epidemic 2004. Available at
<http://www.unaids.org/EN/Geographical+Area/by+country/thailand.asp>.
- Shapiro, M.F., Morton, S.C. and McCaffrey, D.F. 1999. "Variations in the care of HIV -infected adults in the United State: Results from the HIV cost and services utilization study", J Am Med Assoc. 281(24), 2305-2315.
- Shelton, MJ., Ritterman, Y. and Esch, L.D. Provider identified adverse drug reactions in HIV patients:prevalence and characterizations. Accepted for presentation at the ACCP Annual Meeting, Los Angeles, CA, November 2000.
- Stein, DS., Korvick, J.A., Vermund, S.H. 1992. "CD4 lymphocyte cell enumeration for

- prediction of clinical course of human immunodeficiency virus disease: a review” J Infect Dis. 165, 352-363.
- Strand, L.M., Mourley, PC., Cipolle, R.J., Ramsey, R. and Lamsam, G.D. 1990. “Drug related problem:their structure and function.DICP”, Ann Pharmacother. 24, 1093-1097.
- Williams, A., Friedland, G. 1997. “Adherence compliance and HAART”. AIDS Clin Care. 9(7), 51-54.